NEW IQVIA INSTITUTE REPORT WARNS OF ACCESS DISPARITIES FOR CAR T-CELL THERAPY ACROSS EUROPE Stockley Park, UK – 23 April 2025 – A new report reveals disparities in chimeric antigen receptor (CAR) ...

In a report released yesterday, Matthew Biegler from Oppenheimer maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a ...

The biotech Gilead Sciences has been the best-performing healthcare stock in the S&P 500 by far over the past 12 months. Its ...

Gilead Sciences, Inc. ( NASDAQ: GILD) Q1 2025 Earnings Conference Call April 24, 2025 4:30 PM ET Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial ...

Gilead Sciences releases its first-quarter results after Thursday's closing bell. Here's a look at the details from the report.

Shares of Gilead Sciences, Inc. (GILD) traded nearly 3% lower in pre-market on Friday after the company reported ...

Gain key insights from Gilead Sciences' Q1 2025 earnings call, featuring strong HIV sales, Lenacapavir launch updates, and market trends shaping ...

Despite steep budget and staffing cuts at the FDA in recent weeks and other headwinds, Gilead CEO Daniel O’Day assured investors that the pharma’s plans and preparations for lenacapavir’s launch ...

DelveInsight's "IBRANCE Market Size, Forecast, and Market Insight Report" highlights the details around IBRANCE, a CDK4/6 ...

Dodge & Cox’s January 2025 personnel update suggests that by year’s end, a generational leadership change that began to take shape at least six years ago will be complete. Careful planning has ...

A good choice for an actively managed equity income approach. Our research team assigns Silver ratings to strategies that they have a high conviction will outperform the relevant index, or most ...

At close: April 17 at 4:00:00 PM EDT ...